Table 3.
Patients showing high maximal mutation frequency slope (MMFS)
| Patient | MMFS* | Fast growing mutations | MCF1 (%) | MCF2 (%) | dT (moths) | Treatment | Richter syndrome transformation |
|---|---|---|---|---|---|---|---|
| #52 | 117.7 | TP53 (P152+) | 2.1 | 11.4 | <1 | None | Yes |
| #68 | 9.1 | TP53 (R273C) | 0.0 | 100.0 | 11 | None | No |
| #51 | 6.7 | SF3B1 (I704F) | 12.2 | 68.9 | 5 | RCVP | Yes |
| #37 | 6.4 | TP53 (R248Q) | 3.8 | 90.0 | 10 | RDHAOX | Yes |
| #57 | 5.9 | NOTCH1 (P2514-) | 0.8 | 94.2 | 12 | None | Yes |
| #47 | 4.6 | del13q | 37.6 | 100.0 | 13 | None | No |
| #14 | 3.9 | del17p | 18.9 | 90.0 | 16 | A | No |
| #42 | 3.4 | TP53 (N239T) | 0.0 | 100.0 | 16 | RDHAOX | Yes |
| #4 | 3.3 | del17p | 53.6 | 100.0 | 15 | CLB-O | No |
| #54 | 3.0 | NOTCH1 (P2415-) | 100.0† | 100.0 | 22 | FCO | No |
| #22 | 2.9 | BIRC3 deletion | 0.0 | 93.9 | 29 | FCR | No |
| #20 | 2.8 | del13q | 0.0 | 100.0 | 36 | CLB | No |
| #63 | 2.5 | BIRC3 (M388V) | 0.0 | 86.0 | 24 | FCR | Yes |
| #6 | 2.3 | del17p | 0.0 | 92.1 | 34 | CLB | No |
| #38 | 2.3 | NOTCH1 (P2514-) | 41.7 | 42.9 | 4 | CVP | Yes |
| #13 | 2.2 | TP53 (G136H) | 0.0 | 100.0 | 45 | RDHAOX | No |
| #1 | 2.1 | del11q | 11.8 | 100.0 | 41 | FCR/A/BR | No |
MMFS, maximal mutation frequency slope (in standard deviation per year); MCF1, mutation cell frequency of selected mutation at the first time point; MCF2, mutation cell frequency at the second time point; dT, the elapsed time between two samples; RCVP, rituximab, cyclophosphamide, vincristine, prednisone; RDHAOX, rituximab, dexamethasone, high dose cytarabine, oxaliplatin; A, alemtuzumab; CLB-O, chlorambucil, ofatumumab; FCO, fludarabine, cyclophosphamide, ofatumumab; FCR, fludarabine, cyclophosphamide, rituximab; CLB, chlorambucil; CVP, rituximab, cyclophosphamide, vincristine, prednisone; BR, bendamustine, rituximab.
Total number of the cancer cells with NOTCH1 alteration does not change, but the allele frequency of the mutation increases because of the deletion of the wild-type allele.